REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Fortis Pharmaceuticals Sp. z o.o. (Poland)

Main Activities: Other Miscellaneous Nondurable Goods Merchant Wholesalers
Full name: Fortis Pharmaceuticals Sp. z o.o. Profile Updated: September 22, 2023
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Polish Download a sample report

Fortis Pharmaceuticals is a pharmaceutical company that focuses on developing medical products, including Xylometazolin Fortis Pharmaceuticals, Fortis Pharmaceuticals, and Simetic Fortis Pharmaceuticals. Fortis Pharmaceuticals claims to be committed to innovation and quality in the healthcare industry.

Headquarters
Ul. Adama Mickiewicza 29
Katowice; Slaskie; Postal Code: 40-085

Contact Details: Purchase the Fortis Pharmaceuticals Sp. z o.o. report to view the information.

Website: http://www.fortispharmaceuticals.pl

Basic Information
Total Employees:
Purchase the Fortis Pharmaceuticals Sp. z o.o. report to view the information.
Outstanding Shares:
Purchase the Fortis Pharmaceuticals Sp. z o.o. report to view the information.
Registered Capital:
Purchase the Fortis Pharmaceuticals Sp. z o.o. report to view the information.
Incorporation Date:
September 16, 2021
Key Executives
Purchase this report to view the information.
President
Purchase this report to view the information.
Vice President
Ownership Details
Purchase this report to view the information.
50%
Purchase this report to view the information.
50%
Company Performance
Financial values in the chart are available after Fortis Pharmaceuticals Sp. z o.o. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency PLN. Absolute financial data is included in the purchased report.
Net sales revenue
29.31%▲
Total operating revenue
34.65%▲
Operating profit (EBIT)
58.76%▲
EBITDA
55.74%▲
Net Profit (Loss) for the Period
102.94%▲
Total assets
18.41%▲
Total equity
129.92%▲
Operating Profit Margin (ROS)
2.37%▲
Net Profit Margin
4.25%▲
Return on Equity (ROE)
-7.51%▼
Debt to Equity Ratio
-74.11%▼
Quick Ratio
0.14%▲

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo